Kakabadze Ann, Mardaleishvili Konstantine, Loladze George, Karalashvili Lia, Chutkerashvili Gocha, Chakhunashvili David, Kakabadze Zurab
Department of Clinical Anatomy, Tbilisi State Medical University, 0177 Tbilisi, Georgia.
Department of Molecular and Translational Medicine, Institute of Medical Research, Ilia State University, 0177 Tbilisi, Georgia.
Oncol Lett. 2017 Mar;13(3):1811-1818. doi: 10.3892/ol.2017.5647. Epub 2017 Jan 25.
The gold standard following segmental mandibulectomy is vascularized autologous bone graft in the form of the fibula flap. However, in bone reconstruction the use of autogenous bone does not always guarantee a successful outcome. The aim of the present investigation was to develop a novel biologically active bone (BAB) graft, and to use it for the reconstruction of large size defects of the mandible bone following tumor resection. In the first part of the present study, biologically active bone graft was developed by using human freeze-dried bone marrow stem cells (BMSCs) paracrine factors and three-dimensional bone scaffold derived from cancellous bovine bone following decellularization. In the second part of the research, one male and three female patients with primary tumors of the mandible underwent hemimandibulectomy. The mandibular bone defects following tumor resection were reconstructed with autogenous rib grafts in three patients and BAB graft was used in one patient. The graft-host interfaces were covered with decellularized human amnion/chorion membrane graft. All patients were followed-up every five months following the reconstruction of the mandible, with no complications observed. Preliminary clinical investigations demonstrated that a BAB graft containing freeze-dried BMSC paracrine factors may be used for the reconstruction of large mandibular bone defects following tumor resection.
节段性下颌骨切除术后的金标准是以腓骨瓣形式的带血管自体骨移植。然而,在骨重建中使用自体骨并不总是能保证成功的结果。本研究的目的是开发一种新型生物活性骨(BAB)移植物,并将其用于肿瘤切除后下颌骨大尺寸缺损的重建。在本研究的第一部分,通过使用人冻干骨髓干细胞(BMSC)旁分泌因子和脱细胞后的松质牛骨来源的三维骨支架来开发生物活性骨移植物。在研究的第二部分,一名男性和三名女性下颌骨原发性肿瘤患者接受了半侧下颌骨切除术。三名患者用自体肋骨移植物重建肿瘤切除后的下颌骨缺损,一名患者使用了BAB移植物。移植物-宿主界面覆盖有脱细胞人羊膜/绒毛膜移植物。下颌骨重建后,所有患者每五个月随访一次,未观察到并发症。初步临床研究表明,含有冻干BMSC旁分泌因子的BAB移植物可用于肿瘤切除后下颌骨大尺寸缺损的重建。